GlassScriptPhysician profile
Carlos Barbur
NPI 1588169585
$5,252.79
in general payments reported to CMS, 2019-2025
35 companies · $1,749 in 2025
The $1,749 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.57 · 2020: $19.94 · 2021: $102 · 2022: $410 · 2023: $897 · 2024: $2,057 · 2025: $1,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,095 · Education: $608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,094.55 |
| Education | $607.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $724.38 | 2021-2025 | |
| Janssen Biotech, INC. | $425.71 | 2024-2025 | Erleada, Tecvayli, Darzalex |
| Novartis Pharmaceuticals Corporation | $388.64 | 2024-2025 | |
| Seagen INC. | $385.22 | 2022-2024 | Tukysa, Tivdak |
| Daiichi Sankyo INC. | $354.20 | 2024-2025 | Enhertu, Datroway |
| Genzyme Corporation | $327.48 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $299.20 | 2019-2025 | Calquence, Enhertu, Lynparza |
| Merck Sharp & Dohme LLC | $285.82 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $285.52 | 2024-2025 | Reblozyl |
| Sobi, INC | $283.85 | 2023-2024 | |
| Lilly USA, LLC | $216.06 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Incyte Corporation | $191.06 | 2022-2023 | Jakafi |
| Abbvie INC. | $167.68 | 2022-2024 | Venclexta |
| Jazz Pharmaceuticals INC. | $89.61 | 2023-2025 | Zepzelca |
| Deciphera Pharmaceuticals INC. | $87.73 | 2021-2024 | Qinlock |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $78.18 | 2024-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $74.17 | 2023-2025 | Ninlaro, Iclusig |
| Glaxosmithkline, LLC. | $68.94 | 2023-2025 | Ojjaara, Blenrep, Zejula |
| Eisai INC. | $60.67 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.23 | 2025 | |
| Taiho Oncology, INC. | $45.67 | 2022-2025 | |
| Mirati Therapeutics, INC. | $44.21 | 2024 | Krazati |
| Tempus Ai, INC | $37.32 | 2024 | Xt Cdx |
| Boston Scientific Corporation | $34.66 | 2025 | Ams 700 |
| Amgen INC. | $30.79 | 2021-2023 | Riabni, Mvasi, Lumakras |
| Astellas Pharma US INC | $29.69 | 2023 | Xtandi |
| Array Biopharma INC | $23.77 | 2024 | Mektovi, Braftovi, Lorbrena |
| Genentech USA, INC. | $23.10 | 2023 | Phesgo, Perjeta |
| Tolmar, INC. | $22.57 | 2023 | |
| Emd Serono, INC. | $20.00 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $19.96 | 2021 | |
| Sun Pharmaceutical Industries INC. | $19.64 | 2023 | Odomzo, Yonsa |
| Puma Biotechnology, INC. | $17.85 | 2024 | |
| Pharmacosmos Therapeutics INC. | $17.23 | 2023 | Monoferric |
| Teva Pharmaceuticals USA, INC. | $14.98 | 2024 | Truxima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Barbur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.